

Applicants: Peter S. Linsley et al.  
Serial No.: 722,101  
Filed: June 27, 1991  
Page 2

Please amend the subject application as follows:

In the Claims:

Please cancel claims 13, 14, 25 and 59-62 without prejudice to applicants' right to pursue protection for the subject matter defined by these claims if applicants determine to do so in a continuation or divisional application in the future.

Please amend claims 15, 21, 19, and 26 as follows.

D<sup>1</sup> --9. (amended) The method of claim 1, wherein said B7 antigen is immobilized to eucaryotic host cells to crosslink CD28 receptor on said T cells.--

D<sup>2</sup> --15. (X3 Amended) The method of claim 1 further comprising adding anti-CD[3]2 antibody to co-react with said T cells.--

D<sup>3</sup> --17. (amended) The method of claim 1, wherein said T cells are reacted with [B cells expressing] B7 antigen or B7Ig and said T cell responses are stimulated.

D<sup>4</sup> --19. (X2 Amended) A method of regulating functional T cell responses of CD28 positive T cells comprising reacting B7 positive cells with [a ligand reactive with B7 antigen] a monoclonal antibody designated BB-1 or a F(ab)<sub>2</sub> fragment thereof or the CD28Ig fusion protein.--

D<sup>5</sup> --21. (X3 amended) The method of claim 19, wherein the ligand is a Fab fragment of a monoclonal antibody reactive with B7 antigen and [CD 28] CD28 positive T cell responses are inhibited.--

Applicants: Peter S. Linsley et al.  
Serial No.: 722,101  
Filed: June 27, 1991  
Page 3

16  
--26. (X2 Amended) The method of claim 19, wherein said ligand is [CD28 receptor] a polypeptide having an amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of the CD28 antigen and said CD28 positive T cell responses are inhibited.--

#### REMARKS

Claims 1, 3, 5-15, 17-42, 47, 49, 51-57, 59-65, and 67-77 are pending. Claims 67-76 have been withdrawn as directed to a non-elected invention. Claims 13, 14, 25 and 59-62 have been canceled without prejudice. Claims 15, 21, 19, and 26 have been amended. Accordingly, claims 1, 3, 5-12, 15, 17-24, 26-42, 47, 49, 51-57, 63-65, and 77 are presently being examined.

Support for the changes to the claims may be found in the specification as originally filed as follows.

Support for amended claim 9 may be found in the specification at page 12, lines 29-31.

Support for amended claim 15 may be found in the specification at page 7, lines 15-16.

Support for amended claim 17 may be found in the specification at page 8, lines 15-17.

Support for amended claim 19 may be found in the specification at page 23, lines 13-18.

Support for amended claim 26 may be found in the specification at page 8, lines 1-6.